Cosmo's Rifamycin Gel Meets Primary Endpoint in Phase 2 Ulcerative Colitis Trial

• Cosmo announced positive Phase 2 results for rifamycin 1% topical gel in distal ulcerative colitis and ulcerative proctitis on October 19, 2026.
• The trial met its primary endpoint, with more patients achieving clinical remission than with placebo.
• Treatment was well tolerated, with no unexpected safety findings or treatment-related serious adverse events.
• Discussions with the FDA and EMA will guide Phase 3 planning.
• Topline results have been announced; full results will be presented at upcoming major medical meetings or congresses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmo NV published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.